OBJECTIVES: To evaluate the immunohistochemical profile of a carcinoid (low grade neuroendocrine tumor of the kidney) from a patient with lymph node positive disease who remains disease free for 31 months after radical nephrectomy, lymph node dissection, and adjuvant therapy with sunitinib malate. METHODS: Immunohistochemical staining was performed for chromogranin, synaptophysin, CD31, VEGF, HIF-1α, HIF-2, and Glut-1. Staining was evaluated in 3 high-power fields and samples scored as strongly positive (3+), moderately positive (2+), weakly positive (1+), or negative (0). A clear cell renal cell carcinoma was used as positive control. RESULTS: Immunohistochemical staining was strongly positive VEGF, weak to moderately positive for HIF-2, and negative for HIF-1α and Glut-1. CONCLUSIONS: Our case of primary renal carcinoid stained intensely for VEGF and HIF-2, consistent with a VHL-HIF1-HIF2-Glut1 independent pathway for VEGF activation. These data suggest that like other neuroendocrine tumors, primary renal carcinoid is a potential target for anti-angiogenic therapy with sunitinib.
OBJECTIVES: To evaluate the immunohistochemical profile of a carcinoid (low grade neuroendocrine tumor of the kidney) from a patient with lymph node positive disease who remains disease free for 31 months after radical nephrectomy, lymph node dissection, and adjuvant therapy with sunitinib malate. METHODS: Immunohistochemical staining was performed for chromogranin, synaptophysin, CD31, VEGF, HIF-1α, HIF-2, and Glut-1. Staining was evaluated in 3 high-power fields and samples scored as strongly positive (3+), moderately positive (2+), weakly positive (1+), or negative (0). A clear cell renal cell carcinoma was used as positive control. RESULTS: Immunohistochemical staining was strongly positive VEGF, weak to moderately positive for HIF-2, and negative for HIF-1α and Glut-1. CONCLUSIONS: Our case of primary renal carcinoid stained intensely for VEGF and HIF-2, consistent with a VHL-HIF1-HIF2-Glut1 independent pathway for VEGF activation. These data suggest that like other neuroendocrine tumors, primary renal carcinoid is a potential target for anti-angiogenic therapy with sunitinib.
Authors: Donna E Hansel; Jonathan I Epstein; Ema Berbescu; Samson W Fine; Robert H Young; John C Cheville Journal: Am J Surg Pathol Date: 2007-10 Impact factor: 6.394
Authors: Matthew H Kulke; Heinz-Josef Lenz; Neal J Meropol; James Posey; David P Ryan; Joel Picus; Emily Bergsland; Keith Stuart; Lesley Tye; Xin Huang; Jim Z Li; Charles M Baum; Charles S Fuchs Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Bonnie Wang; Rosa I Sanchez; Ronald B Franklin; David C Evans; Su-Er W Huskey Journal: Drug Metab Dispos Date: 2004-08-10 Impact factor: 3.922
Authors: Jun Zhang; Zhiliang Jia; Qiang Li; Liwei Wang; Asif Rashid; Zhenggang Zhu; Douglas B Evans; Jean-Nicolas Vauthey; Keping Xie; James C Yao Journal: Cancer Date: 2007-04-15 Impact factor: 6.860